MIL-OSI Economics: Global partnerships to foster Singapore Project RESET against cardiovascular diseases, says GlobalData

Source: GlobalData

Global partnerships to foster Singapore Project RESET against cardiovascular diseases, says GlobalData

Posted in Medical Devices

Given the rising prevalence of cardiovascular diseases (CVDs) among Singapore’s aging population, the National University of Singapore (NUS) Medicine has taken proactive steps with initiatives such as MOMENTUM-CVD and Project RESET to develop preventive measures. International collaborations are expected to strengthen these efforts, considerably advancing cardiovascular research in the country, says GlobalData, a leading data and analytics company.

Agilent Technologies Inc. has recently formed a strategic partnership with the NUS, through NUS Medicine, to establish a Center of Excellence in Cell Metabolism. This collaboration aims to advance research in cardiovascular and metabolic diseases over the next four years.

Shreya Jain, Medical Devices Analyst at GlobalData, comments: “Global collaborations such as Duke-NUS partnership and Global Alliance for Chronic Diseases are significantly advancing Singapore’s initiatives for CVD research and prevention by providing access to international expertise, technology, and funding. Partnerships with global leaders such as Agilent Technologies and academic institutions are likely to further enhance the country’s capabilities in developing innovative solutions for CVDs.”

Agilent’s integrated metabolic and cellular phenotyping platforms such as xCELLigence, Seahorse XF, and BioTek technologies are said to offer multimodal workflow solution, enabling cell studies at exceptional speed and scale. Such combinations will facilitate the discovery of new therapeutic targets and cardio-liver-metabolic biomarkers to prevent CVDs.

Jain concludes: “By developing innovative, preventative healthcare strategies and enhancing local expertise in cardiovascular research, Singapore aims to reduce healthcare costs associated with CVDs. Furthermore, international collaborations will elevate Singapore’s status as a hub for biomedical research, attracting investment, talent, and boosting the local economy over time.”

MIL OSI Economics